α-halogenoacrylic derivatives of antitumor agents

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 81-94

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Cruz Lopez, Olga ^a   Lopez Cara, Carlota ^a   Preti, Delia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

bromoacryloyl; Antitumor agents; Apoptosis; Distamycin A; Hybrid molecules

Indexed keywords

1 O ACETYLBRITANNILACTONE; 1,4 FLUOROANILIDE DERIVATIVE; ALPHA BROMOACRYLIC ANILIDE DERIVATIVE; ALPHA HALOGENOACRYCLIC DERIVATIVE; ALPHA METHYLENE BUTYROLACTONE DERIVATIVE; ANILIDE; ANTINEOPLASTIC AGENT; BENZO HETEROCYCLIC ALPHA BROMOACRYLOYL AMIDE DERIVATIVE; BENZO[4,5]IMIDAZO[1,2 D][1,2,4]THIADIAZOLE DERIVATIVE; BROSTALLICIN; CYTOTOXIC AGENT; DESFORMYLDISTAMYCIN A DERIVATIVE; DISTAMYCIN A; DISTAMYCIN A DERIVATIVE; DOXORUBICIN; GAMMA BUTYROLACTONE DERIVATIVE; HELENALIN; METHYLENOLACTOCIN; N,N' DIMETHYLAMINOANILIDE DERIVATIVE; PNU 151807; PROTOLICHESTERINIC ACID; SESQUITERPENE LACTONE DERIVATIVE; TALLIMUSTINE; UNCLASSIFIED DRUG; ALKYLATING AGENT; GUANIDINE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLOIMINOQUINONE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; IC 50; LEUKEMIA; MITOSIS INHIBITION; MOLECULAR INTERACTION; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW; SOFT TISSUE SARCOMA; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DISTAMYCINS; GUANIDINES; HUMANS; MICE; PYRROLES; PYRROLOIMINOQUINONES;

EID: 62749121651     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787001640     Document Type: Review

References (48)

1. Hartley, J.A.; Lown, J.W.; Mattes, W.B.; Kohn, K.W. DNA sequence specificity of antitumor agents. Oncogenes as possible targets for cancer therapy. Acta Oncol., 1998, 27, 503-10.
2. Perry, N.B.; Blunt, J.W.; Munro, H.M.G.; Higa, T.; Sakai, R. Discorhabdin D, an antitumor alkaloid from the sponges Latrunculia brevis and Prianos sp. J. Org. Chem., 1988, 53, 4127-8.
3. Perry, N.B.; Blunt, J.W.; Munro, H.M.G. Cytotoxic pigments from New Zealand sponges of the genus Latrunculia: discorhabdins A, B and C. Tetrahedron, 1988, 44, 1727-34.
4. Perry, N.B.; Blunt, J.W.; Mc Combs, J. D.; Munro, H.M.G. Discorhabdin C, a highly cytotoxic pigment from a sponge of the genus Latrunculia. J. Org. Chem., 1986, 51, 5476-8.
5. Antunes, E.M.; Beukes, D.R.; Kelly, M.; Samaai, T.; Barrows, L.R.; Marshall, K.M.; Sincich, C.; Davies-Coleman, M.T. Cytotoxic pyrroloiminoquinones from four new species of South African latrunculid sponges. J. Nat. Prod., 2004, 67, 1268-76.
6. For reviews specifically focused on Distamycin A see: a) Cozzi, P.; Mongelli, N. Cytotoxics derived from distamycin A and congeners. Curr. Pharm. Des., 1998, 4, 181-201;
7. b) Bailly, C.; Chaires, J.B. Sequence-Specific DNA Minor Groove Binders. Design and Synthesis of Netropsin and Distamycin Analogs. Bioconjug. Chem., 1998, 9, 513-38;
8. c) Baraldi, P.G.; Cacciari, B.; Spalluto, G.; Romagnoli, R. DNA minor groove alkylating agents structurally related to distamycin A. Expert Opin. Ther. Pat., 2000, 6, 891-904;
9. d) Marchini, S.; Broggini, M.; Sessa, C.; D'Incalci, M. Development of distamycin-related DNA binding anticancer drugs. Expert Opin. Invest. Drugs, 2001; 10, 1703-14;
10. e) Cozzi, P. The discovery of a new potential anticancer drug: a case history. Il Farmaco, 2003, 58, 213-20.
11. Arcamone, F.; Penco, S.; Orezzi, P.G.; Nicolella, V.; Pirelli, A. Structure and synthesis of distamycin A. Nature, 1964, 203, 1064-5.
12. Lee, S.; Inselburg, J. In vitro sensitivity of Plasmodium falciparum to drugs that bind DNA or inhibit its synthesis. J. Parasitol., 1993, 79, 780-2.
13. Pelton, J.G.; Wemmer, D.E. Binding modes of distamycin A with d(CGCAAATTTGCG)2 determined by two-dimensional NMR. J. Am. Chem. Soc., 1990, 112, 1393-9.
14. Arcamone, F. M.; Animati, F.; Barbieri, B.; Configliacchi, E.; D'Alessio, R.; Geroni, C.; Giuliani, F. C.; Lazzari, E.; Menozzi, M.; Mongelli, N.; Penco, S.; Verini, M. A. Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. J. Med. Chem., 1989, 32, 774-8.
15. D'Alessio, R.; Geroni, C.; Biasioli, G.; Pesenti, E.; Grandi, M.; Mongelli, N. Structure-activity relationship of novel distamycin A derivatives: Synthesis and antitumor activity. Bioorg. Med. Chem. Lett., 1994, 4, 1467-72.
16. Marchini, S.; Cirò, M.; Gallinari F.; Geroni, C.; Cozzi, P.; D'Incalci, M.; Broggini, M. α-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. Br. J. Cancer, 1999, 80, 991-7.
17. Ghielmini, M.; Bosshard, G.; Capolongo, L.; Geroni, C.; Pesenti E.; Torri, V.; D'Incalci, M. Estimation of the hematological toxicity of minor groove alkylators using tests on human cord blood cells. Br. J. Cancer, 1997, 75, 878-83.
18. Viallet, J.; Stewart, D.; Shepherd, F.; Ayoub, J.; Cormier, Y.; Di Pietro, N.; Steward, W. Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Lung Cancer, 1996, 15, 367-73.
19. Baraldi, P.G.; Beria, I.; Cacciari, B.; Capolongo, L.; Cozzi, P.; Mongelli, N.; Romagnoli, R.; Spalluto, G. Synthesis and antitumor activity of novel distamycin derivatives. Bioorg. Med. Chem. Lett., 1996, 6, 1241-6.
20. Baraldi, P. G.; Romagnoli, R.; Beria, I.; Cozzi, P. Geroni, C.; Mongelli, N.; Bianchi, N.; Mischiati, C.; Gambari, R. Synthesis and Antitumor Activity of New Benzoheterocyclic Derivatives of Distamycin A. J. Med. Chem., 2000, 43, 2675-84.
21. Romagnoli, R.; Baraldi, P.G.; Iaconinoto, M.A.; Carrion, M.D.; Tabrizi, M.A.; Gambari, R.; Borgatti, M.; Heilmann. J. Synthesis and biological activity of alpha-bromoacryloyl lexitropsin conjugates. Eur. J. Med. Chem., 2005, 40, 1123-8.
22. Lee, H. H.; Boyd, M.; Gravatt, G. L.; Denny, W. A. Pyrazole analogs of the bispyrrolecarboxamide anti-tumor antibiotics: synthesis, DNA binding and anti-tumor properties. Anti Cancer Drug Des., 1991, 6, 501-17.
23. Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Golberg, J. A. CC-1065 and the Duocarmycins: Synthetic Studies. Chem. Rev., 1997, 97, 787-828.
24. Kaizerman, J. A.; Gross, M. I.; Ge, Y.; White, S.W.; Hu, J.-X. Duan, Baird, E. B.; Johnson, K.W.; Tanaka, R.D.; Moser, H.E.; Burli, R.W. DNA Binding Ligands Targeting Drug-Resistant Bacteria: Structure, Activity, and Pharmacology. J. Med. Chem., 2003, 46, 3914-29.
25. Cozzi, P.; Beria, I.; Caldarelli, M.; Geroni, C.; Monelli, N.; Pannella, G. Cytotoxic α-bromoacrylic derivatives of distamycin analogs modified at the amidino moiety. Bioorg. Med. Chem. Lett., 2000, 10, 1273-6.
26. Beria, I.; Baraldi, P.G.; Cozzi, P.; Caldarelli, M.; Geroni, C.; Marchini, S.; Mongelli, N.; Romagnoli, R. Cytotoxic α-Halogenoacrylic Derivatives of Distamycin A and Congeners. J. Med. Chem., 2004, 47, 2611-23.
27. Geroni, C.; Pannella, G.; Capolongo, L. Antitumor Activity of PNU 166196, a Novel DNA Minor Groove Binder Selected for Clinical Development. Proc. AACR Ann. Meeting, 2000, 41, 265 (Abstract 2708).
28. Geroni, C.; Marchini, S.; Cozzi, P.; Galliera, E.; Ragg, E.; Colombo, T.; Battaglia, R.; Howard, M.; D'Incalci, M.; Broggini, M. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res., 2002, 62, 2332-6.
29. Tsuchida, S., Sato, K. Glutathione transferases and cancer. Crit. Rev. Biochem. Mol. Biol., 1992, 27, 337-84.
30. Beria, I.; Caldarelli, M.; Geroni, C.; Monelli, N.; Reinach, B.; Vignati, L.; Cozzi, P. Cytotoxic α-Bromoacrylic derivatives of low molecular weight. Bioorg. Med. Chem. Lett., 2002, 12, 1467-71.
31. Baraldi, P. G.; Beria, I.; Cozzi, P.; Bianchi, N.; Gambari, R.; Romagnoli, R. Synthesis and growth inhibition activity of α.-Bromoacrylic heterocyclic and benzoheterocyclic derivatives of distamycin A modified on the amidino moiety. Bioorg. Med. Chem. 2003, 11, 965-75.
32. Cozzi, P.; Beria, I.; Caldarelli, M.; Capolongo, L.; Geroni, C.; Mongelli, N. Cytotoxic halogenoacrylic derivatives of distamycin A. Bioorg. Med. Chem. Lett., 2000, 10, 1269-72.
33. Garner, P.; Dogan, O.; Pillai, S. Auxiliary mediated synthesis of aziridine-2-carboxylic acid. Tetrahedron Lett., 1994, 35, 1653-6.
34. Tagliabue, G.; Pifferi, A.; Balconi, G.; Mascellani, E.; Geroni, C.; D'Incalci, M.;Ubezio, P. Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting antineoplastic agents. Int. J. Cancer, 1993, 54, 435-42.
35. Lee, K.H.; Hall, I.H.; Mar, E.C.; Starnes, C.O.; El Gebaly, S.A.; Waddell, T.G.; Hadgraft, R.I.; Ruffner, C.G.; Weidner, I. Sesquiterpene antitumor agents: inhibitors of cellular metabolism. Science, 1977, 196, 533-6.
36. Spring, O.; Albert, K.; Gradmann, W. Annuithrin, a new biologically active germacranolide from Helianthus annuus. Phytochemistry, 1981, 20, 1883-5.
37. Liu, S.; Liu, H.; Yan, W.; Zhang, L.; Bai, N.; Ho, C.-T. Studies on 1-O-acetylbritannilactone and its derivative, (2-O-butyloxime-3-phenyl)-propionyl-1-O-acetylbritannilactone ester. Bioorg. Med. Chem. Lett., 2004, 14, 1101-4.
38. Park, B.K.; Nakagawa, M.; Hirota, A.; Nakayama, M. Methylenolactocin, a novel antitumor antibiotic from Penicillium sp. J. Antibiot., 1988, 41, 751-8.
39. Cavallito, C.J.; Fruehauf, D.M.; Bailey, J.H. Lactone aliphatic acids as antibacterial agents. J. Am. Chem. Soc., 1948, 70, 3724-6.
40. Willuhn, G.; Merfort, I.; Pabreiter, C.M.; Schimdt, T.J. In " Advances in Compositae Systematics"; Hind, D.J.N.; Jeffrey, C.; Pope, G.V., Eds.; Royal Botanic Gardens: Kew, 1995, 167-195.
41. Kupchan, S.M., Fessler, C.D.; Eakin, M.; Giacobbe, T.J. Reactions of alpha methylene lactone tumor inhibitors with model biological nucelophiles. Science, 1970, 168, 376-8.
42. Romagnoli, R.; Baraldi, P.G.; Tabrizi, M. A.; Bermejo, J.; Estévez, F.; Borgatti, M.; Gambari, R. Design, Synthesis, and Biological Evaluation of Hybrid Molecules Containing.alpha.-Methylene -.gamma.-Butyrolactones and α.-Bromoacryloyl Moieties. J. Med. Chem., 2005, 48, 7906-10.
43. a) Leung-Toung, R.; Li, W.;Tam, T.F.; Karimian, K. Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem., 2002, 9, 979-1002;
44. b) Scozzafava, A.; Casini, A.; Supuran, C.T. Targeting cysteine residues of biomolecules: New approaches for the design of antiviral and anticancer drugs. Curr. Med. Chem., 2002, 9, 1167-85
45. Newton, C.G.; Ollis, D.W.; Wright, D.E. Cyclic meso-ionic compounds. Part 23. Novel chemistry of 1,2,4-thiadiazoles and their transformation into meso-ionic 1,2,4-thiadiazolium derivatives. J. Chem. Soc. Perkin Trans 1, 1984, 75-84.
46. Leung-Toung, R.;Wodzinska, J.; Li, W.; Lowrie, J.; Kukreja, R.; Desilets, D.; Karimian, K., Tam, T.F. 1,2,4-Thiadiazole: A novel Cathepsin B inhibitor. Bioorg. Med. Chem., 2003, 11, 5529-37.
47. Tam, T.F.; Leung-Toung, R.; Li, W.; Spino, M.; Karimian, K. Medicinal chemistry and properties of 1,2,4-thiadiazoles. Mini Rev. Med. Chem., 2005, 5, 367-79.
48. Romagnoli, R.; Baraldi, P.G.; Carrion, M. D; Cruz-Lopez, O.; Preti, D.; Tabrizi, M. A.; Fruttarolo, F.; Heilmann, J.; Bermejo, J.; Estévez, F. Hybrid molecules containing benzo[4,5]imidazo1,[1,2-d] [1,2,4]thiadiazole and α.-bromoacryloyl moieties as potent apoptosis inducers on human myeloid leukemia cells. Bioorg. Med. Chem. Lett., 2007, 17, 2844-8.